Results 21 to 30 of about 2,602 (175)

Update on hepatitis C virus resistance to direct-acting antiviral agents [PDF]

, 2014
Review[Abstract] Resistance to direct-acting antiviral (DAA) agents against hepatitis C virus (HCV) infection is driven by the selection of mutations at different positions in the NS3 protease, NS5B polymerase and NS5A proteins.
Cachay, Edward, Castro-Iglesias, Ángeles, Mena, Álvaro, Pedreira, José D., Poveda, Eva, Wyles, David L.   +5 more
core   +2 more sources

Oral direct-acting antivirals and the incidence or recurrence of hepatocellular carcinoma:a systematic review and meta-analysis [PDF]

, 2018
Background: The influence of direct-acting antiviral (DAA) therapy for chronic hepatitis C virus on the risk of hepatocellular carcinoma (HCC) is conflicting.
Akuta, Alonso, ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Electronic address: stanislas.pol@aphp.fr, Cabibbo, Calleja, Cheung, Conti, Dfr, Eletreby, Grandhe, Hagiwara, Jakobsen, Kanwal, Kobayashi, Kolly, Kozbial, Lacombe, Li, Maan, Nagata, Ogata, Ouzzani, Piroth, Reddy, Reig, Rodríguez-Osorio, Terrault, Torres, Virlogeux, Waziry, Wei, Zavaglia   +31 more
core   +1 more source

A hepatitis C-vírus-fertőzés és kezelésének költségvonzata [PDF]

, 2015
Absztrakt A hepatitis C-vírus-fertőzés a Föld lakosságának 2–3%-át érinti és a betegséghez társuló egyéni következmények mellett igen jelentős össztársadalmi gazdasági problémát jelent.
Hunyady, Béla, Makara, Mihály
core   +1 more source

The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients

Gut and Liver, 2018
Background/AimsAlthough daclatasvir with asunaprevir was approved in Japan for interferon ineligible or intolerant patients, patients aged ≥75 years were excluded in the phase III trial. The present study aimed to evaluate the safety and efficacy of this
Shinya Taki, Hideyuki Tamai, Yoshiyuki Ida, Naoki Shingaki, Akira Kawashima, Ryo Shimizu, Kosaku Moribata, Takao Maekita, Mikitaka Iguchi, Jun Kato, Taisei Nakao, Masayuki Kitano   +11 more
doaj   +1 more source

New all‐oral HCV therapies for genotype 1: A final good‐bye to interferon [PDF]

, 2014
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/107533/1/cld369 ...
Lok, Anna S.F.
core   +1 more source

Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C.

PLoS ONE, 2019
AimsDrug-induced liver damage characterized by serum alanine aminotransferase (ALT) elevation often occurs in direct-acting antiviral (DAA) combination therapy for chronic hepatitis C virus (HCV) infection.
Keizo Kato, Noritomo Shimada, Masanori Atsukawa, Hiroshi Abe, Norio Itokawa, Yoshihiro Matsumoto, Rie Agata, Akihito Tsubota   +7 more
doaj   +1 more source

Evaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1. [PDF]

PLoS ONE, 2016
The aim of this study was to evaluate the efficacy of daclatasvir plus asunaprevir therapy in patients infected with hepatitis C virus and determine its relevance to resistant variants.A total of 629 consecutive patients infected with hepatitis C virus ...
Tatsuya Ide, Yuichiro Eguchi, Masaru Harada, Kunihide Ishii, Masaru Morita, Yasuyo Morita, Gen Sugiyama, Hirofumi Fukushima, Yoichi Yano, Kazunori Noguchi, Hiroki Nakamura, Junjiro Hisatomi, Hiroto Kumemura, Miki Shirachi, Shinji Iwane, Michiaki Okada, Yuichi Honma, Teruko Arinaga-Hino, Ichiro Miyajima, Kei Ogata, Reiichiro Kuwahara, Keisuke Amano, Toshihiro Kawaguchi, Ryoko Kuromatsu, Takuji Torimura, DAAs Multicenter Study Group   +25 more
doaj   +1 more source

Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C. [PDF]

, 2017
Background and Aims: Recurrent infection of hepatitis C virus (HCV) in liver transplant (LT) recipients is universal and associated with significant morbidity and mortality.
Bau, Sherona N, Busuttil, Ronald W, Choi, Gina, Durazo, Francisco A, El-Kabany, Mohammed M, Esmailzadeh, Negin L, Fong, Tiffany M, Grotts, Jonathan, Han, Steven-Huy B, Jimenez, Melissa A, Kachadoorian, Caterina A, Kang, Susan, Mai, Michelle H, Ramirez, Samantha D, Rheem, Justin, Saab, Sammy   +15 more
core   +1 more source

Hepatitis C-vírus-fertőzés: diagnosztika, antivirális terápia, kezelés utáni gondozás. [PDF]

, 2015
Magyarországon 70000 egyén lehet fertőzött hepatitis C-vírussal, nagyobbik részük nem tud a fertőzöttségéről. A fertőzés időben történő felfedezése és meggyógyítása a beteg szempontjából a munkaképesség megőrzését, az életminőség javulását, a májzsugor ...
Gerlei, Zsuzsanna, Gervain, Judit, Horváth, Gábor, Hunyady, Béla, Lengyel, Gabriella, Makara, Mihály, Pár, Alajos, Rókusz, László, Szalay, Ferenc, Tornai István (1954-) (belgyógyász, gasztroenterológus), Tornai, István, Werling, Klára, †Telegdy, László   +12 more
core   +2 more sources

Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis

Gut and Liver, 2019
Background/Aims We evaluated the efficacy and safety of daclatasvir (DCV) and asunaprevir (ASV) in patients with chronic hepatitis C virus (HCV) infection on hemodialysis. Methods : We performed a single-arm, multicenter prospective study.
Byung Seok Lee, Myeong Jun Song, Jung Hyun Kwon, Tae Hee Lee, Ji Woong Jang, Seok Hyun Kim, Sae Hwan Lee, Hong Soo Kim, Ji Hoon Kim, Seok Bae Kim, Soon Young Ko, Do Seon Song   +11 more
doaj   +1 more source